Mostrar el registro sencillo del ítem

dc.contributor.authorNovo-Rodríguez, Cristina
dc.contributor.authorGarcía Fontana, Beatriz 
dc.contributor.authorLuna Del Castillo, Juan De Dios 
dc.contributor.authorAndujar Vera, Francisco
dc.contributor.authorÁvila Rubio, Verónica
dc.contributor.authorGarcía Fontana, Cristina 
dc.contributor.authorMorales Santana, Sonia
dc.contributor.authorRozas Moreno, Pedro
dc.contributor.authorMuñoz Torres, Manuel Eduardo 
dc.date.accessioned2019-08-13T08:37:59Z
dc.date.available2019-08-13T08:37:59Z
dc.date.issued2018-06-21
dc.identifier.citationNovo-RodrõÂguez C, GarcõÂa-Fontana B, Luna-Del Castillo JDD, AnduÂjar-Vera F,AÂ vila-Rubio V, GarcõÂa-Fontana C, et al. (2018) Circulating levels of sclerostin are associated with cardiovascular mortality. PLoS ONE 13(6): e0199504. [https://doi. org/10.1371/journal.pone.0199504]es_ES
dc.identifier.urihttp://hdl.handle.net/10481/56627
dc.description.abstractCardiovascular diseases are a health problem throughout the world, especially in people with diabetes. The identification of cardiovascular disease biomarkers can improve risk stratification. Sclerostin is a modulator of the Wnt/β-catenin signalling pathway in different tissues, and it has recently been linked to vascular biology. The current study aimed to evaluate the relationship between circulating sclerostin levels and cardiovascular and non-cardiovascular mortality in individuals with and without type 2 diabetes. We followed up a cohort of 130 participants (mean age 56.8 years; 48.5% females; 75 with type 2 diabetes; 46 with prevalent cardiovascular disease) in which serum sclerostin levels were measured at the baseline. Time to death (both of cardiovascular and non-cardiovascular causes) was assessed to establish the relationship between sclerostin and mortality. We found that serum sclerostin concentrations were significantly higher in patients with prevalent cardiovascular disease (p<0.001), and independently associated with cardiovascular mortality (p = 0.008), showing sclerostin to be a stronger predictor of mortality than other classical risk factors (area under the curve = 0.849 vs 0.823). The survival analysis showed that an increase of 10 pmol/L in the serum sclerostin level resulted in a 31% increase in cardiovascular mortality. However, no significant association was observed between sclerostin levels and non-cardiovascular mortality (p = 0.346). From these results, we conclude that high sclerostin levels are related to mortality due to cardiovascular causes. The clinical implication of these findings is based on the possible use of serum sclerostin as a new biomarker of cardiovascular mortality risk in order to establish preventive strategies.es_ES
dc.description.sponsorshipThe authors declare that this work was support in part by Consejería de Salud y Bienestar Social (Junta de Andalucía) Grants (PI0207-2016 to Dr. Beatriz García-Fontana), and Fondo de Investigación Sanitaria (Instituto de Salud Carlos III) Grants (PI12/02141, PI15/01207 to Dr. Manuel Muñoz-Torres), with co-financing from FEDER. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript and there was no additional external funding received for this study.es_ES
dc.language.isoenges_ES
dc.publisherPublic Library of Science (PLOS)es_ES
dc.rightsAtribución 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.titleCirculating levels of sclerostin are associated with cardiovascular mortalityes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES
dc.identifier.doi10.1371/journal.pone.0199504


Ficheros en el ítem

[PDF]

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 3.0 España
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 3.0 España